German China

USA: Cancer Therapy Manufacturing Partnership to Promote Understanding of T Cell Biology

Editor: Alexander Stark

Thermo Fisher Scientific and biotechnology company Lyell Immunopharma are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients.

Related Company

Thermo Fisher Scientific and Lyell Immunopharma announced the formation of a Cell Therapy Manufacturing partnership.
Thermo Fisher Scientific and Lyell Immunopharma announced the formation of a Cell Therapy Manufacturing partnership.
(Source: Thermo Fisher)

Waltham/USA — The fitness of T cells poses a challenge in manufacturing cell therapies. To overcome this hurdle, Thermo Fisher Scientific and Lyell Immunopharma have formed a manufacturing partnership. The cooperation is also intended to support Lyell with the development of an integrated yet flexible cGMP-compliant platform including reagents, consumables and instrumentation.

The intent of this strategic partnership is to gain access and insights into emerging and existing technologies to improve the robustness and consistency of manufacturing operations. This alliance is also to provide the opportunity for further strategic collaboration in supply chain and commercialization pathways.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:46749545)